Pegasys (pegylated interferon α -2a) / Roche |
NCT02604823: A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 307 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 11/05 | 11/05 | | |
NCT02570191: A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 60 | Europe | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 02/07 | 02/07 | | |
NCT00226382: Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment |
|
|
| Completed | 4 | 50 | RoW | Pegylated Interferon-alfa-2a | Chinese University of Hong Kong, Hoffmann-La Roche | Chronic Hepatitis B | 04/08 | 04/08 | | |
NCT01519921: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 150 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 06/08 | 06/08 | | |
NCT02791269: A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program |
|
|
| Completed | 4 | 24 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 07/08 | 07/08 | | |
NCT00291616: Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B |
|
|
| Completed | 4 | 52 | RoW | Pegylated Interferon-alpha2a, Thymosin alpha1 & Pegylated Interferon-alpha2a | Seoul National University Hospital, Roche Pharma AG, SciClone Pharmaceuticals | Chronic Hepatitis B | 08/08 | 08/08 | | |
NCT02598063: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 255 | RoW | Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 04/09 | 04/09 | | |
NCT01787279: An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B |
|
|
| Completed | 4 | 59 | RoW | Peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 05/09 | 05/09 | | |
NCT00487747: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. |
|
|
| Completed | 4 | 18 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00614471: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 219 | RoW | Entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00436163 / 2006-005370-49: A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 39 | Europe | Peginterferon alfa-2a, Pegasys® | Hoffmann-La Roche | Hepatitis B, Chronic | 05/10 | 05/10 | | |
NCT00435825 / 2006-000870-63: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). |
|
|
| Completed | 4 | 551 | US, Europe, RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/10 | 12/10 | | |
NCT00940485: A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 200 | RoW | entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/11 | 12/11 | | |
NCT01086085: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive |
|
|
| Completed | 4 | 265 | RoW | Adefovir, peginterferon alfa-2a [PEGASYS] | Hoffmann-La Roche, Major Science and Technology Special Project of China Eleventh Five-year | Hepatitis B, Chronic | 03/13 | 03/13 | | |
| Completed | 4 | 184 | Europe, RoW | pegylated interferon a-2a, Pegasys, Entecavir, Baraclude | Foundation for Liver Research | Chronic Hepatitis B | 07/13 | 07/13 | | |
NCT01277601 / 2010-024586-45: Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B |
|
|
| Completed | 4 | 751 | US, Canada, Europe, RoW | TDF, Viread®, Peg-IFN, Pegasys® | Gilead Sciences | Chronic Hepatitis B | 08/14 | 07/15 | | |
NCT00922207: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 280 | RoW | Adefovir, Entecavir, Placebo, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 09/14 | 09/14 | | |
NCT00927082: A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 383 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
NCT01179594: A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. |
|
|
| Withdrawn | 4 | 0 | NA | entecavir, peginterferon alfa-2a [Pegasys], placebo | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
NCT01938781: Optimized Treatment and Regression of HBV-induced Liver Fibrosis |
|
|
| Completed | 4 | 400 | RoW | entecavir, entecavir dispersible tablets, Peg-IFN, Pegasys | Beijing Friendship Hospital, Peking University People's Hospital, RenJi Hospital, Peking University, Shanghai Zhongshan Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Public Health Clinical Center, Nanfang Hospital of Southern Medical University, Sir Run Run Shaw Hospital, Beijing YouAn Hospital, Peking University First Hospital, Beijing 302 Hospital, Peking Union Medical College Hospital, Beijing Ditan Hospital, Beijing Tiantan Hospital, Huashan Hospital, Tongji Hospital, Tang-Du Hospital, Fifth Hospital of Shijiazhuang City, Logistics University of Chinese People's Armed Police Forces, The First Affiliated Hospital of Shanxi Medical University, The Affiliated Hospital of Yanbian University | Liver Fibrosis | 12/16 | 12/16 | | |
E+VIP, NCT02097004: Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection |
|
|
| Completed | 4 | 111 | RoW | Peginterferon alfa-2a, Pegasys, HBV vaccination, Euvax B Inj, Entecavir, Baracrude | Seoul National University Hospital | Hepatitis B, Chronic | 01/18 | 03/18 | | |
NCT03084250: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC |
|
|
| Active, not recruiting | 4 | 150 | RoW | Peginterferon Alfa-2A, Pegasys, Adefovir, entecavir,tenofovir, either of them | Shanghai Nanhui Nanhua Hospital | Hepatitis B | 04/23 | 12/23 | | |